

D4 found with rapid-release Glucophage®. This means that overall patient exposure to metformin (in both the Example 3 formulation and the Glucophage®) is equivalent. ---

IN THE CLAIMS

Please amend claims 22 and 56 to read as follows:

17
1922
183
DB (Amended) The pharmaceutical formulation as defined in Claim 21 wherein the ionic polymer comprises sodium alginate, carbomer, calcium carboxymethylcellulose or sodium carboxymethylcellulose, and the non-ionic polymer comprises hydroxypropylmethylcellulose 2208 USP, viscosity grade ranging from about 4000 to about 100,000 cps and/or hydroxypropylmethyl cellulose 2910 USP viscosity grade ranging from about 3 to about 150 cps.

42
56
411
De (Amended) The pharmaceutical formulation as defined in Claim 55 wherein the ionic polymer comprises sodium alginate, carbomer, calcium carboxymethylcellulose or sodium carboxymethylcellulose, and the non-ionic polymer comprises hydroxypropylmethylcellulose 2208 USP, viscosity grade ranging from about 4000 to about 100,000 cps and/or hydroxypropylmethyl cellulose 2910 USP viscosity grade ranging from about 3 to about 150 cps.

Remarks

The definitions of hydroxypropyl methylcellulose 2208 USP and 2910 USP were inadvertently reversed at page 21, lines 16 and 19 of the specification. Applicants have attached to this Amendment pages 387 and 388 from the United States Pharmacopeia, 20th Revision, Official from July 1, 1980 showing that hydroxypropylmethylcellulose 2208 has a methoxyl content of 19- 24% and a hydroxypropyl content of 4 - 12% whereas hydroxypropylmethylcellulose 2910 has a methoxy content of 28 - 30% and a hydroxypropyl content of 7 - 12%. The attachment also shows